Ultragenyx Q1 2024 revenue $109M (+8% YoY); net loss $171M; reaffirms guidance; pipeline advances

Ultragenyx Pharmaceutical Inc.

2024-Q1 EPS reported -$2.03 revenue$108,833,000

Q1 total revenue $109M (+8% YoY); Crysvita $83M (+9%), Dojolvi $16M (+14%).
Net loss $171M ($2.03 per share) vs $164M ($2.33) in Q1 2023; operating expenses $274M.
Reaffirmed 2024 guidance: total revenue $500-530M, Crysvita $375-400M, Dojolvi $75-80M, cash use <$400M.
Positive interim Phase 1/2 GTX-102 data for Angelman syndrome; OI Phase 3 enrollment complete; DTX401 data expected Q2 2024.
Cash and equivalents $569M as of March 31, 2024; net cash used in operations $191M in Q1.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Ultragenyx Pharmaceutical Inc. reported quarter ended March 31, 2024 results: revenue $109 million, net income net loss of $171 million, or $2.03 per share basic and diluted, EPS $2.03 per share basic and diluted. Guidance reaffirmed.

Period: quarter ended March 31, 2024
Revenue: $109 million
Net income: net loss of $171 million, or $2.03 per share basic and diluted
EPS: $2.03 per share basic and diluted
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Pharmaceutical Inc. Investors Joshua Higa ir@ultragenyx.com Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update First quarter total revenue of $109 million, Crysvita® revenue of $83 million and Dojolvi® revenue of $16 million Reaffirmed 2024 expected total revenue guidance between $500 million to $530 million, Crysvita revenue of

View on SEC.gov

379 earnings releases filed in the last 30 days. Browse all earnings releases →

Ultragenyx Pharmaceutical Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-052052

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.